Together with our previously published results [11], the current data demonstrate that the GADD45β/MKK7-targeting strategy to pharmacologically inhibit oncogenic NF-κB signalling succeeds in coupling safety with therapeutic anticancer efficacy, resulting in ablation of MM xenografts in mouse models and selective killing of primary human MM cells through a mechanism involving JNK-driven apoptosis, whilst producing no significant adverse effect and none of the dose-limiting toxicities of conventional IKKβ/NF-κB-targeting drugs [[2], [3], [4], [5], [6],10]. The gene discussed is GADD45B; the disease is Miyoshi myopathy.